{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:02:57Z","timestamp":1777590177862,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Buruli ulcer Groningen"},{"name":"Junior Scientific Master Class, University of Groningen"},{"DOI":"10.13039\/100016315","name":"American Leprosy Missions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-70890-w","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T11:01:56Z","timestamp":1724842916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection"],"prefix":"10.1038","volume":"14","author":[{"given":"Sandor-Adrian","family":"Klis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ymkje","family":"Stienstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kabiru M.","family":"Abass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justice","family":"Abottsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel O.","family":"Mireku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjip S.","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"70890_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clindermatol.2008.09.021","volume":"27","author":"F Portaels","year":"2009","unstructured":"Portaels, F., Silva, M. T. & Meyers, W. M. Buruli ulcer. Clin. Dermatol. 27, 291\u2013305. https:\/\/doi.org\/10.1016\/j.clindermatol.2008.09.021 (2009).","journal-title":"Clin. Dermatol."},{"key":"70890_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S0140-6736(03)14417-0","volume":"362","author":"TS van der Werf","year":"2003","unstructured":"van der Werf, T. S., Stinear, T., Stienstra, Y., van der Graaf, W. T. & Small, P. L. Mycolactones and Mycobacterium ulcerans disease. Lancet 362, 1062\u20131064. https:\/\/doi.org\/10.1016\/S0140-6736(03)14417-0 (2003).","journal-title":"Lancet"},{"key":"70890_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.283.5403.854","volume":"283","author":"KM George","year":"1999","unstructured":"George, K. M. et al. Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283, 854\u2013857 (1999).","journal-title":"Science"},{"key":"70890_CR4","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1128\/aac.00175-07","volume":"51","author":"A Chauty","year":"2007","unstructured":"Chauty, A. et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51, 4029\u20134035. https:\/\/doi.org\/10.1128\/aac.00175-07 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70890_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/cid\/ciq072","volume":"52","author":"A Chauty","year":"2011","unstructured":"Chauty, A. et al. Oral treatment for Mycobacterium ulcerans infection: Results from a pilot study in Benin. Clin. Infect. Dis. 52, 94\u201396. https:\/\/doi.org\/10.1093\/cid\/ciq072 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"70890_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S0140-6736(09)61962-0","volume":"375","author":"WA Nienhuis","year":"2010","unstructured":"Nienhuis, W. A. et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: A randomised controlled trial. Lancet 375, 664\u2013672. https:\/\/doi.org\/10.1016\/S0140-6736(09)61962-0 (2010).","journal-title":"Lancet"},{"key":"70890_CR7","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1128\/AAC.02165-13","volume":"58","author":"RO Phillips","year":"2014","unstructured":"Phillips, R. O. et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 58, 1161\u20131166. https:\/\/doi.org\/10.1128\/AAC.02165-13 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70890_CR8","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1128\/AAC.00299-10","volume":"54","author":"FS Sarfo","year":"2010","unstructured":"Sarfo, F. S. et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 54, 3678\u20133685. https:\/\/doi.org\/10.1128\/AAC.00299-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70890_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002739","volume":"8","author":"S Klis","year":"2014","unstructured":"Klis, S. et al. Long term streptomycin toxicity in the treatment of Buruli Ulcer: Follow-up of participants in the BURULICO drug trial. PLoS Negl. Trop. Dis. 8, e2739. https:\/\/doi.org\/10.1371\/journal.pntd.0002739 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"70890_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/0091270005284854","volume":"46","author":"B Gurley","year":"2006","unstructured":"Gurley, B. et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol. 46, 201\u2013213. https:\/\/doi.org\/10.1177\/0091270005284854 (2006).","journal-title":"J. Clin. Pharmacol."},{"key":"70890_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1043-6618(05)80021-0","volume":"32","author":"MS Benedetti","year":"1995","unstructured":"Benedetti, M. S. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol. Res. 32, 177\u2013187 (1995).","journal-title":"Pharmacol. Res."},{"key":"70890_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2165\/00003088-200746120-00004","volume":"46","author":"S Eberl","year":"2007","unstructured":"Eberl, S. et al. Role of p-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46, 1039\u20131049. https:\/\/doi.org\/10.2165\/00003088-200746120-00004 (2007).","journal-title":"Clin. Pharmacokinet."},{"key":"70890_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-0711-5-3","volume":"5","author":"J Chen","year":"2006","unstructured":"Chen, J. & Raymond, K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann. Clin. Microbiol. Antimicrob. 5, 3 (2006).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"70890_CR14","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1128\/AAC.00099-10","volume":"54","author":"JW Alffenaar","year":"2010","unstructured":"Alffenaar, J. W. et al. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob. Agents Chemother. 54, 3878\u20133883. https:\/\/doi.org\/10.1128\/AAC.00099-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70890_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0149-2918(01)80060-6","volume":"23","author":"DR Guay","year":"2001","unstructured":"Guay, D. R. et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther. 23, 566\u2013577 (2001).","journal-title":"Clin. Ther."},{"key":"70890_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijantimicag.2006.03.029","volume":"28","author":"S Grau","year":"2006","unstructured":"Grau, S. et al. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int. J. Antimicrob. Agents 28, 249\u2013252. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.03.029 (2006).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"70890_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1310\/9FEX-MHQQ-74L6-GGCJ","volume":"6","author":"MA Jacobson","year":"2005","unstructured":"Jacobson, M. A., Nicolau, D. P., Sutherland, C., Smith, A. & Aweeka, F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV. Clin. Trials. 6, 246\u2013253. https:\/\/doi.org\/10.1310\/9FEX-MHQQ-74L6-GGCJ (2005).","journal-title":"HIV. Clin. Trials."},{"key":"70890_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/S0149-2918(00)83040-4","volume":"22","author":"JL Adler","year":"2000","unstructured":"Adler, J. L. et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin. Ther. 22, 1410\u20131420 (2000).","journal-title":"Clin. Ther."},{"key":"70890_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0149-2918(00)83041-6","volume":"22","author":"JJ Murray","year":"2000","unstructured":"Murray, J. J. et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin. Ther. 22, 1421\u20131432 (2000).","journal-title":"Clin. Ther."},{"issue":"10232","key":"70890_CR20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0140-6736(20)30047-7","volume":"395","author":"RO Phillips","year":"2020","unstructured":"Phillips, R. O. et al. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: A randomised, open-label, non-inferiority phase 3 trial. Lancet 395(10232), 1259\u20131267. https:\/\/doi.org\/10.1016\/S0140-6736(20)30047-7 (2020).","journal-title":"Lancet"},{"key":"70890_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejps.2014.10.018","volume":"67","author":"A Olivares-Morales","year":"2015","unstructured":"Olivares-Morales, A., Kamiyama, Y., Darwich, A. S., Aarons, L. & Rostami-Hodjegan, A. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur. J. Pharm. Sci. 67, 32\u201344. https:\/\/doi.org\/10.1016\/j.ejps.2014.10.018 (2015).","journal-title":"Eur. J. Pharm. Sci."},{"key":"70890_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1128\/AAC.47.4.1228-1232.2003","volume":"47","author":"L Marsollier","year":"2003","unstructured":"Marsollier, L. et al. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob. Agents Chemother. 47, 1228\u20131232 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70890_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/bdd.767","volume":"32","author":"K Togami","year":"2011","unstructured":"Togami, K., Chono, S. & Morimoto, K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm. Drug Dispos. 32, 389\u2013397. https:\/\/doi.org\/10.1002\/bdd.767 (2011).","journal-title":"Biopharm. Drug Dispos."},{"key":"70890_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1128\/AAC.38.4.876","volume":"38","author":"DN Fish","year":"1994","unstructured":"Fish, D. N., Gotfried, M. H., Danziger, L. H. & Rodvold, K. A. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob. Agents Chemother. 38, 876\u2013878 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70890_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1128\/AAC.35.4.760","volume":"35","author":"RH Gelber","year":"1991","unstructured":"Gelber, R. H., Siu, P., Tsang, M. & Murray, L. P. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob. Agents Chemother. 35, 760\u2013763 (1991).","journal-title":"Antimicrob. Agents Chemother."},{"key":"70890_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.talanta.2013.12.043","volume":"121","author":"DH Vu","year":"2014","unstructured":"Vu, D. H. et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS\/MS. Talanta 121, 9\u201317. https:\/\/doi.org\/10.1016\/j.talanta.2013.12.043 (2014).","journal-title":"Talanta"},{"key":"70890_CR27","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.2174\/138161211797470174","volume":"17","author":"DH Vu","year":"2011","unstructured":"Vu, D. H., Alffenaar, J. W., Edelbroek, P. M., Brouwers, J. R. & Uges, D. R. Dried blood spots: A new tool for tuberculosis treatment optimization. Curr. Pharm. Des. 17, 2931\u20132939. https:\/\/doi.org\/10.2174\/138161211797470174 (2011).","journal-title":"Curr. Pharm. Des."},{"key":"70890_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0962-8479(95)90551-0","volume":"76","author":"C Zent","year":"1995","unstructured":"Zent, C. & Smith, P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber. Lung Dis. 76, 109\u2013113. https:\/\/doi.org\/10.1016\/0962-8479(95)90551-0 (1995).","journal-title":"Tuber. Lung Dis."},{"key":"70890_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0010-4825(92)90011-B","volume":"22","author":"JH Proost","year":"1992","unstructured":"Proost, J. H. & Meijer, D. K. MW\/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med. 22, 155\u2013163 (1992).","journal-title":"Comput. Biol. Med."},{"key":"70890_CR30","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1128\/AAC.42.8.2070","volume":"42","author":"F Portaels","year":"1998","unstructured":"Portaels, F., Traore, H., De Ridder, K. & Meyers, W. M. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42, 2070\u20132073 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"70890_CR31","doi-asserted-by":"publisher","first-page":"e0007126","DOI":"10.1371\/journal.pntd.0007126","volume":"13","author":"MP Arenaz-Callao","year":"2019","unstructured":"Arenaz-Callao, M. P. et al. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening. PLoS Negl. Trop. Dis. 13(1), e0007126. https:\/\/doi.org\/10.1371\/journal.pntd.0007126 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"70890_CR32","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1128\/AAC.00052-06","volume":"50","author":"B Ji","year":"2006","unstructured":"Ji, B. et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50, 1921\u20131926. https:\/\/doi.org\/10.1128\/AAC.00052-06 (2006).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70890-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70890-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70890-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T11:04:00Z","timestamp":1724843040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70890-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70890"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70890-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19963"}}